UCB HCT in FLT3+ AML

Oncotarget. 2017 Sep 19;8(47):81733-81734. doi: 10.18632/oncotarget.21048. eCollection 2017 Oct 10.

Authors

Celalettin Ustun¹, Annalisa Ruggeri¹, Daniel J Weisdorf¹

Affiliation

¹ Celalettin Ustun: Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

No abstract available

Keywords: AML; FLT3; hematopoietic cell transplantation; relapse; umbilical cord blood.

Publication types

Editorial

Grants and funding

P01 CA065493/CA/NCI NIH HHS/United States